biostudies-literatureUnknown51(4)Pilgram LCharité - Universitätsmedizin Berlin<h4>Objectives</h4>The use of remdesivir (RDV) as the first drug approved for coronavirus disease 2019 (COVID-19) remains controversial. Based on the Lean European Open Survey on severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected patients (LEOSS), we aim to contribute timing-focused complementary real-world insights to its evaluation.<h4>Methods</h4>SARS-CoV-2 infected patients between January 2020 and December 2021 treated with RDV were matched 1:1 to controls considering sociodemographics, comorbidities and clinical status. Multiple imputations were used to account for missing data. Effects on fatal outcome were estimated using uni- and multivariable Cox regression models.<h4>Results</h4>We included 9,687 patients. For those starting RDV administration in the complicatInfection1033-1049https://www.ebi.ac.uk/biostudies/studies/S-EPMC9913009biostudies-literatureUse and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study.PMC9913009Pilgram Lde Miranda SMNHellwig KAppel KSStecher MVehreschild MJGTVom Dahl JSpinner CDHertenstein BHower MJensen BOWille KRuethrich MMKoll CEMHanses FHaselberger MWesthoff TVehreschild JJfalseUse and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study.<h4>Objectives</h4>The use of remdesivir (RDV) as the first drug approved for coronavirus disease 2019 (COVID-19) remains controversial. Based on the Lean European Open Survey on severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected patients (LEOSS), we aim to contribute timing-focused complementary real-world insights to its evaluation.<h4>Methods</h4>SARS-CoV-2 infected patients between January 2020 and December 2021 treated with RDV were matched 1:1 to controls considering sociodemographics, comorbidities and clinical status. Multiple imputations were used to account for missing data. Effects on fatal outcome were estimated using uni- and multivariable Cox regression models.<h4>Results</h4>We included 9,687 patients. For those starting RDV administration in the complicat2023-01-01T00:00:00Z2023 Aug2025-04-04T13:08:23.454Z2025-04-04T13:08:23.454ZS-EPMC99130093676328510.1007/s15010-023-01994-0